Michael Gorin, MD
Ophthalmology · Los Angeles, CANPI 1578536462
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,500 of the $1,583 with a category attached, or 94.7%. Merck accounts for 94.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $1,520 and has fallen 98.9% since, to $16 in 2025.
Across 4 payments — averaging $395.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Illumina, Inc.$47
- Regeneron Healthcare Solutions, Inc.$20
- AbbVie$16
Across 17 payments — averaging $9836.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$167K
What the payments were for
- Consulting fees$1,50095%
- Food & beverage$835%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $1,500 |
| Illumina, Inc. | 1 | $47 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| AbbVie | 1 | $16 |
How this compares
$1,583 in reported general payments places this provider in the 55th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cyclosporine | 12 | $4,354 |
| Difluprednate | 17 | $2,742 |
| Acetazolamide | 23 | $1,741 |
| Dorzolamide Hcl | 70 | $1,523 |
| Prednisolone Acetate | 16 | $1,071 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $624 |
| Latanoprost | 32 | $533 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Los Angeles
- Andrew MoshfeghiLos Angeles$895K
- Barry SeibelLos Angeles$835K
- Nicole FramLos Angeles$551K
- Neda ShamieLos Angeles$547K
- David BoyerLos Angeles$406K
- David HamiltonLos Angeles$359K
- Arjan HuraLos Angeles$306K
- Firas RahhalLos Angeles$264K
- Kouros NourimahdaviLos Angeles$258K
- Daniel RootmanLos Angeles$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.